Scientific Opinion on the substantiation of health claims related to ipriflavone and maintenance of bone mineral density (ID 1872) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 7, Issue 10, 2009, Pages

[No Author Info available]

Author keywords

bone; bone mineral density; health claims; Ipriflavone; post menopausal women

Indexed keywords

EID: 84966874166     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2009.1267     Document Type: Article

References (9)

1. Agnusdei D and Bufalino L, 1997. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcified Tissue International, 61, S23–S27.
2. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone multicenter european fracture study, 2001. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA, 285, 1482–1488.
3. Gambacciani M, Spinetti A, Piaggesi L, Cappagli B, Taponeco F, Manetti P, Weiss C, Teti GC, Lacommare P, Facchini V, 1994. Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists. Bone and Mineral, 26, 19–26.
4. Gennari C, Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Bufalino L, Passeri M, 1998. Effect of ipriflavone - a synthetic derivative of natural isoflavones - on bone mass loss in the early years after menopause. Menopause, 5, 9–15.
5. Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S, 1999. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausalwomen with low bone mass. Logo, 51, 178–183.
6. Pagano L, Teofili L, Mele L, Piantelli M, Ranelletti FO, Equitani F, Larocca LM, Leone G, 1999. Oral ipriflavone (7-isopropoxy-isoflavone) treatment for elderly patients with resistant acute leukemias. Ann. Oncol., 10, 124–125.
7. Reginster JY, 1993. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner., 23, 223–232.
8. Sato Y, Kuno H, Kaji M, Saruwatari N, Oizumi K, 1999. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. Am. J. Phys. Med. Rehabil., 78, 457–463.
9. Somekawa Y, Chiguchi M, Ishibashi T, Wakana K, Aso T, 2001. Efficacy of ipriflavone in preventing adverse effects of leuprolide. J. Clin. Endocrinol. Metab., 86, 3202–3206.